Precision BioSciences, Tiziana Life Ink Foralumab Deal For Cancer Indications

by Vandana Singh, Benzinga Editor

September 2, 2021 9:42 AM | 1 min read |

Precision BioSciences Inc DTIL and Tiziana Life Sciences plc TLSA have announced an exclusive license agreement for Tiziana's foralumab.
The companies plan to explore the fully human anti-CD3 monoclonal antibody as an agent to induce tolerance of allogeneic CAR T cells.
Under the terms of the agreement, Precision gains an exclusive license to use foralumab as a lymphodepletion agent in conjunction with its allogeneic CAR T therapeutics for the treatment of cancers.
Precision will be responsible for the development, commercialization, and costs. Tiziana will receive an upfront payment, certain milestone payments, and royalties.
Specific deal terms were not disclosed.
Price Action: DTIL stock is +1.17% at $13.85, and TLSA stock is up 19.6% at $1.97 during the market session on the last check Thursday.

Posted In: Biotech Long Ideas News Penny Stocks Health Care Contracts Small Cap Movers Trading Ideas General Briefs oncology

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.